Medical device industry pioneer Paul Trainor dies
23 January, 2006 by Michael HirshornPaul Trainor AO, 78, 'father of Australia's medical device industry' died on January 13, 2006.
Phylogica to collaborate with Canadian biotech
20 January, 2006 by Helen SchullerPerth-based Phylogica (ASX:PYC) has entered into an international collaboration agreement with Canadian biotechnology company Axela Biosensors to fast track the discovery new drug candidates for inflammatory disease.
Burrill expects good year for biotech
20 January, 2006 by Ruth BeranThe year 2006 will be a good one for biotech, according to San Francisco's bullish biotech maven, Steve Burrill.
Govts should stay out of agbiotech business: Raff
20 January, 2006 by Graeme O'NeillGovernment involvement in agricultural biotech industries is stifling innovation, a leading industry figure has warned.
Anadis hopes to extend Travelan uses
20 January, 2006 by Helen SchullerMelbourne biopharma Anadis (ASX:ANX) is investigating the use of its over-the-counter traveller's diarrhoea product, Travelan, for additional gastrointestinal therapeutic indications.
NeuroDiscovery and CSIRO sign collaboration agreement
19 January, 2006 by Helen SchullerPerth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) and the CSIRO have entered into a research collaboration agreement.
Drug giant Roche to offer clinical services
19 January, 2006 by Ruth BeranIn what it believes is an industry first, Roche Pharmaceuticals will offer its clinical development services to outside customers, particularly non-government organisations (NGOs), according to the drug giant's global head of clinical pharmacology development, Prof Graham McClelland.
Norwood in bid to buy Dutch vaccine firm
19 January, 2006 by Helen SchullerImmune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has entered into an option to acquire all the share capital of Netherlands-based Bestewil Holding, the 100 per cent owner of Virosome Biologicals Group, for up to 25 million euros (AUD$40.5 million).
Triple whammy may inhibit Tamiflu as bird flu weapon
17 January, 2006 by Graeme O'NeillThe failure of the anti-influenza drug Tamiflu to save the lives of patients with established H5N1 avian influenza infections may be a consequence of the drug's design, mode of delivery, and the uniqueness of the virus itself, according to experts.
FDA wants more data before approving C3's ReCell
16 January, 2006 by Ruth BeranTissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price took a blow today, in the wake of a request by the US Food and Drug Administration (FDA) for more performance data before it can approve C3's ReCell for sale in the US.
EvoGenix touts positive bone treatment results
16 January, 2006 by Helen SchullerEvoGenix (ASX:EGX) has reported results on the development of its product OVP, for the treatment of bone loss.
BioPharmica aims to raise $2.5m
13 January, 2006 by Helen SchullerPerth based BioPharmica (ASX:BPH) has opened a share purchase plan to raise AUD$2.5 million to fund the development of its portfolio of biomedical research.
Antisense to resume MS phase IIa trial
12 January, 2006 by Helen SchullerMelbourne's Antisense Therapeutics (ASX:ANP) has been granted approval to restart the phase IIa trial of its antisense compound ATL1102 for patients with relapsing remitting multiple sclerosis.
LCT raises $3m from mainly US investors
12 January, 2006 by Ruth BeranCell therapy company Living Cell Technologies (ASX:LCT) has raised more than AUD$3 million through a placement of ordinary shares to US shareholders and an Australian investor.
Narhex commences phase I HIV drug trial
11 January, 2006 by Helen SchullerAnti-viral drug developer Narhex Life Sciences (ASX:NLS) has commenced recruitment of healthy volunteers for the phase I clinical trial of its anti-HIV protease inhibitor drug DG17.
